Wolverine Stack Dosage in the Research Literature
What preclinical studies administered to which species, by which route, and for how long. Neither compound is FDA-approved; no human dosing protocol exists.
Animal Study Dosage Parameters for BPC-157 and TB-500
BPC-157 dosage in animal studies follows a consistent range across the published literature. The most common dose in rat musculoskeletal models is 10 µg/kg intraperitoneal, with equipotent effects also observed at 10 ng/kg and, in some tendon models, at 10 pg/kg [1][2]. Oral administration in drinking water has been studied at 0.16 µg/mL (approximately 12 mL per rat per day) and at 10 µg/kg per oral in muscle-to-bone reattachment models [6][7]. Topical administration was studied at 1 µg/g neutral cream in burn wound models [20]. In gastric ulcer models, intramuscular doses of 200–800 ng/kg were used [11].
BPC-157 is notable for its gastric stability — the peptide resists degradation by trypsin and chymotrypsin, enabling oral administration effectiveness in rat models. Most peptides are inactivated by these enzymes within seconds; BPC-157 remains stable in human gastric juice for more than 24 hours [18].
For TB-500 (thymosin beta-4 fragment), published preclinical dosing is based primarily on studies using full-length thymosin beta-4. The dystrophin-deficient mouse study used 150 µg twice weekly over 6 months via intraperitoneal injection [16]. Human Phase 2 trials used topical formulations for wound and ulcer endpoints; a Phase 1 intravenous safety study was conducted (NCT00743769). The TB-500 fragment sold by research vendors is not identical to full-length thymosin beta-4 — most mechanistic research uses full-length Tβ4 or the LKKTET hexapeptide, creating an inference gap for direct TB-500 dosing comparisons.
Wolverine Stack Dosage Reference: Animal Study Parameters
The dosage data from published studies organizes as follows:
BPC-157 — rat models (musculoskeletal)
- Route: intraperitoneal | Dose range: 10 pg/kg – 10 µg/kg | Frequency: daily | Duration: 7–90 days [1][2]
- Route: oral (drinking water) | Dose range: 0.16 µg/mL or 10 µg/kg per oral | Frequency: ad libitum or daily | Duration: 30–90 days [6][7]
- Route: topical (cream) | Concentration: 1 µg/g | Frequency: daily application | Duration: 7–14 days [20]
BPC-157 — rat models (gastric)
- Route: intramuscular or intragastric | Dose range: 200–800 ng/kg | Frequency: single-dose or daily | Duration: acute models [11]
Thymosin beta-4 — mouse models (muscle)
- Route: intraperitoneal | Dose: 150 µg twice weekly | Duration: 6 months [16]
Thymosin beta-4 — human Phase 2 trials (wound healing)
- Route: topical | Formulations: gel and ointment | Populations: venous stasis ulcers, pressure ulcers [22]
None of these parameters constitute a human dosing protocol. They document what was administered in each cited preclinical or clinical study. See the Wolverine stack dosage page for pharmacokinetic context.
Wolverine Stack Research Protocol Overview
The Wolverine stack research protocol — as a concept derived from the published literature — describes what individual studies have used for each component, not a unified validated protocol for the combination.
For BPC-157, the most reproducible preclinical protocol across independent publications is daily intraperitoneal injection at 10 µg/kg starting at the time of injury induction, with functional and histological endpoints assessed at 7 days (acute) to 90 days (chronic repair) [1][2][6]. Some models applied BPC-157 orally in drinking water, demonstrating equivalent efficacy via a different route [6][7].
For thymosin beta-4, the most extended preclinical protocol used twice-weekly intraperitoneal injections of 150 µg over 6 months in a chronic disease model [16]. Acute wound healing protocols used topical application with assessment at 4–7 days [22].
The Wolverine stack protocol overview does not represent a validated co-administration schedule — no published study has defined one.
BPC-157 to TB-500 Ratio: What the Research Shows
No peer-reviewed study has formally optimized the BPC-157:TB-500 ratio in combination. The 1:1 ratio commonly described in community discussions is an anecdotal convention, not a research-derived recommendation [18].
The two compounds have been dosed at substantially different absolute amounts in their respective independent studies: BPC-157 at doses in the microgram-per-kilogram range (as low as 10 pg/kg with reported activity); TB-500 at 150 µg per injection in the mouse model. Direct ratio comparisons are further complicated by the inference gap between the TB-500 fragment and the full-length thymosin beta-4 used in most mechanistic studies.
Study Duration in Preclinical Wolverine Stack Protocols
Preclinical study durations span a wide range depending on the injury model and endpoint. BPC-157 studies in acute tendon and ligament models use 7-day early assessment windows, with full biomechanical endpoints at 28–90 days [1][2]. Chronic injury models — including the spinal cord compression study that applied BPC-157 at day 4 of an established injury — assessed recovery by day 15 [9].
For the thymosin beta-4 muscle regeneration model, the study duration was 6 months — consistent with the timeline required to assess fiber-count changes in a dystrophic disease model [16].
No standardized cycle length is established for the Wolverine stack combination in peer-reviewed literature. Community-described "research cycles" of 4–12 weeks are anecdotal conventions with no published optimization basis.
BPC-157 Pharmacokinetics
BPC-157 pharmacokinetics in rats and dogs showed linear, dose-proportional characteristics. Intravenous half-life was less than 30 minutes — mean 15.2 minutes in rats and 5.27 minutes in dogs [17]. Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs. The compound was rapidly metabolized to small peptide fragments and individual amino acids, excreted via urine and bile [17].
Oral administration in rat models is associated with a substantially longer apparent pharmacokinetic profile — reported at approximately 66–69 hours in some analyses — likely reflecting a different absorption and distribution model rather than the same distribution seen intravenously. BPC-157's resistance to trypsin and chymotrypsin degradation is the key factor enabling oral bioactivity in rats [18].
Human pharmacokinetics for BPC-157 have not been formally characterized. No Phase 1 pharmacokinetic study has been published.
Administration Frequency in Research Protocols
Preclinical studies have used daily and every-other-day subcutaneous or intraperitoneal injection schedules for BPC-157, depending on the model. The Achilles tendon and ligament studies used daily intraperitoneal administration [1][2]. The thymosin beta-4 muscle regeneration study used twice-weekly intraperitoneal injections [16].
No standardized human dosing frequency exists; neither compound is FDA-approved for any human therapeutic use. The dosage parameters in animal studies document the specific schedules used in each cited study.
Timeline Observations in Animal Studies
Animal models show measurable tissue-repair markers at 7–14 days in acute injury models; functional and biomechanical recovery endpoints are typically assessed at 28–90 days in musculoskeletal studies [1][2]. No validated human timeline data exists for the Wolverine stack combination.
BPC-157's intravenous half-life is less than 30 minutes [17], which means the compound clears the systemic circulation rapidly. The mechanism by which rapid clearance leads to persistent tissue-level effects over days or weeks is not fully characterized in the published literature.
Timing Considerations in Research Protocols
Circadian timing effects on BPC-157 or TB-500 activity have not been systematically studied in the published literature. No time-of-day preference — morning versus night administration — is established in any preclinical data for either compound. The published studies have used standardized injection schedules without reference to circadian variables.
Frequency of Administration in Published Protocols
Animal studies have used daily, every-other-day, and twice-weekly injection schedules depending on the injury model and experimental design. Daily intraperitoneal injection is the most common schedule in BPC-157 musculoskeletal studies [1][2][6]. Twice-weekly is used in thymosin beta-4 chronic disease models [16]. No consensus frequency exists for either compound; no human dosing schedule has been validated in controlled trials.